|
OGT Expands MRD Detection Capabilities with New SureSeq Myeloid MRD Plus NGS Panel
hits:83 Date:11/11/25
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs
Oxford, UK – 10th November 2025. Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of expertise in hybrid capture technology, the panel detects ultra-low frequency variants in key MRD-associated biomarkers in acute myeloid leukaemia (AML). This means users of this panel can obtain detailed genomic information, to provide an earlier and more complete picture of their sample's MRD status.
Accurate detection of MRD is a pivotal component in advancing clinical research and improving our understanding of therapeutic strategies for AML. Evidence consistently demonstrates that MRD-negative status is associated with significantly improved long-term outcomes and the ability to sensitively identify even a small number of residual leukemic cells at earlier time points. This provides clinicians and researchers with a more detailed snapshot of disease status.
With targeted coverage of 16 biomarkers associated with AML, including FLT3 and NPM1, the SureSeq Myeloid MRD Plus NGS Panel is optimised for MRD characterisation. Users benefit from robust detection of complex and challenging mutations such as FLT3 internal tandem duplications (ITDs) exceeding 300 base pairs, to ensure they can obtain comprehensive genomic insights from their samples. Additionally, its focused design enables high-precision variant detection without the increased sequencing costs typically associated with broader panels and, by leveraging SureSeq’s refined bait design strategy, the panel achieves exceptional sensitivity, detecting variants at allele frequencies as low as 0.01%.
Complementing the panel is Interpret, OGT’s powerful bioinformatics solution provided at no additional cost* which includes longitudinal visualisation of MRD dynamics over time - including SNVs, indels and ITDs. Available as a secure cloud-based platform or local installation, Interpret offers user-friendly pre-configured analysis pipelines which streamline laboratory workflows and accelerate implementation. Additionally, customisation options allow users to tailor their analysis to meet their specific clinical research needs. The entire panel and bioinformatics solution is supported by OGT’s dedicated team of experts, who provide comprehensive assistance from initial setup with our FAS team through to advanced troubleshooting, ensuring a seamless and confident adoption of MRD detection.
OGT, using their specialised expertise in the development of superior hybridisation-based capture technology, ensures that the SureSeq Myeloid MRD Plus NGS Panel excels in the detection of complex structural variants and helps eliminate inaccurate calls caused by alternative PCR-based approaches.
Graham Speight PhD, Executive Vice President of R&D at OGT said “We are very excited to be launching our latest NGS panel for MRD. Combining our decades of expertise in haemato-oncology and NGS product development has allowed us to offer a panel which helps today’s clinical research labs stay at the forefront of developments in MRD. This latest product provides them with a streamlined tool to detect and analyse the MRD status of their AML samples. By enabling labs to generate more detailed insights into disease progression and post-therapeutic response, this panel helps drive a better understanding of AML.”
For more information about the SureSeq Myeloid MRD Plus NGS Panel and OGT's genomics solutions, please visit: www.ogt.com
For further information, please contact:
Oxford Gene Technology, Unit 5, Oxford Technology Park, 4A Technology Drive, Kidlington, Oxfordshire, OX5 1GN, United Kingdom
T: +441865 856800
E: contact@ogt.com; W: www.ogt.com; Twitter: @OxfordGeneTech
*Subject to Fair Usage policy.
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 30 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at www.ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/
|
中文
